Viral Hepatitis
Copyright ©The Author(s) 2003.
World J Gastroenterol. Jul 15, 2003; 9(7): 1487-1490
Published online Jul 15, 2003. doi: 10.3748/wjg.v9.i7.1487
Table 1 Baseline characteristics of patients
Patients (n)189
Age (year) ± SD58 ± 18
Sex (M/F)95/94
ALT (U/L) ± SE142 ± 8
AST (U/L) ± SE103 ± 7
Genotype 1-4 vs others115 vs 7461 vs 39%
Anti-Hp positive antibody6031.8%
Gastrin (pg/ml)(median ± SE)52.0 ± 10.4
TSH (UI/ml)2.2 ± 0.15
ANA positive (n)3418%
AMA positive (n)-
ASMA positive (n)5730%
LKM positive (n)10.5%
APCA positive (n)31.6%
ATM positive (n)157.8%
Liver histology (n)
CAH without cirrhosis (n)13873%
CAH with cirrhosis (n)5127%
Table 2 Variations of APCA positivity and hypergastrinemia in IFN treated patients
Before IFN n (%)IFN withdrawal n (%)12 mo after withdrawal n (%)
APCA positivity3 (1.6%)25 (13%)a7 (4%)bd
Hypergastrinemia9 (5%)31(16%)a14 (7%)cd
Table 3 Organ-specific and non-organ-specific autoantibodies
Before IFN + (%)IFN withdrawal + (%)12 mo after withdrawal+(%)
Organ-specific antibodies
TPO14 (8.0%)39 (20.6%)a23 (12.2%)
Non-organ-specific antibodies
ANA34 (18.0%)45 (24.0%)41 (22.0%)
SMA56 (30.0%)62 (33.0%)60 (31.0%)
AMA-1 (0.5%)1 (0.5%)
LMK 11 (0.5%)3 (1.6%)2 (1.1%)